['healthy']
['clonidine mbt 50µg', 'clonidine mbt 100µg', 'catapres 100μg']

        Main Inclusion Criteria:

          -  Healthy males or females (non-pregnant/non-lactating) aged 18 - 50 years.

          -  A Body Mass Index (BMI) of 18-30.

          -  No clinically significant abnormal serum biochemistry, haematology and urine
             examination values.

          -  A negative urinary drugs of abuse screen.

          -  Negative HIV and Hepatitis B and C results.

          -  No clinically significant abnormalities in 12-lead electrocardiogram (ECG).

          -  No clinically significant abnormalities in blood pressure or pulse.

          -  No allergy or sensitivity to clonidine or any of its excipients.

          -  No allergy to milk or milk derivatives.

          -  Subjects must provide written informed consent to participate in the study

        Main Exclusion Criteria:

          -  Current or past medical condition that might significantly affect the pharmacokinetic
             or

          -  pharmacodynamic response to clonidine.

          -  Participation in a New Chemical Entity clinical study within the previous 3 months or
             a marketed drug clinical study within the previous 30 days.

          -  Pathological condition of the oral cavity that would affect administration via the
             buccal route.

          -  Raynaud's disease or other peripheral vascular disease.

          -  Receipt of regular medication within 14 days of the first dose that may have an impact
             on the safety and objectives of the study (at the Investigator's discretion).

          -  Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or
             metabolic dysfunction.

          -  Symptomatic postural hypotension evident on screening

          -  History or evidence of Suicidal Ideation and/or behaviour as determined by using
             Columbia-Suicide Severity Rating Scale (C-SSRS)
      